AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Effect of Aspirin Use and Atherosclerotic Cardiovascular Risk on Incidence of Dementia and Alzheimer’s Disease - Insights from a Primary Prevention Registry
By Kainat A, Muluk P, Thoma FW et al.
Background: Atherosclerotic cardiovascular disease (ASCVD) and Alzheimer’s disease (AD) dementia share common risk factors. However, the role of ASCVD prevention therapies (such as lipid lowering therapy [LLT] and antiplatelets) in AD dementia prevention is not fully known. We examined the utilization and effect of LLT and antiplatelets with incident dementia and AD across ASCVD risk profiles in a real-world cohort. Methods: We used data from primary prevention registry derived from a large healthcare network spanning>400 clinical sites. Multivariable Cox proportional models were generated to study incidence of dementia and AD, stratified by ASCVD risk profiles. Impact of aspirin (no-use, low-use, and high-use categories based on frequency of reported use) and LLT (statin or ezetimibe use) on AD dementia was assessed in fully adjusted models. Results: Among n= 347,128, 2.4% developed dementia and 2.0% developed AD dementia over a median follow-up of 7.94 years. Aspirin and LLT use highest in high ASCVD risk group (48.4%, and 52.9%), followed in a graded manner amongst moderate (37.7%, and 44.1%) and low-risk (20% and 28.8%) groups. Similarly, for AD dementia patients, aspirin and LLT use was highest in high ASCVD risk (48.2%, and 52.7%), followed by moderate (37.8% and 44.1%) and low risk (19.3% and 30.2%) group. In adjusted models, incident dementia (HR , 2.59; 95% CI [2.29-2.92] for high risk, and HR, 1.93; 95% CI [1.76-2.12] for intermediate risk) and AD dementia (HR , 2.85; 95% CI [2.49-3.25] for high risk, and HR, 2.07; 95% CI [1.87-2.30] for intermediate risk) was higher in high risk patients ( Table 1 ). Low and high-use aspirin among high ASCVD risk had lower incident dementia (HR, 0.88; 95% CI, [0.77-1.00] and HR, 0.83; 95% [CI 0.77-0.90]) and AD dementia (HR, 0.83; 95% CI [0.77-0.91] and HR, 0.85; 95% CI [0.73-0.97]). (Table 2 ) Similarly, low dose LLT use among high ASCVD risk group offered risk reduction in incident dementia (HR, 1.82; 95% CI [1.18-2.82]for low dose LLT vs HR, 2.89; 95% CI [ 2.50-3.36] for no therapy) and AD dementia (HR, 2.22; 95% CI [1.32-3.72] for low dose LLT vs HR, 3.23; 95% CI [2.74-3.80] for no LLT). (Table 3) Conclusion: In this cohort of primary prevention adults, underlying ASCVD risk was associated with higher risk of incident dementia and AD. Individuals with high baseline ASCVD 10-year risk derived benefit from statin and aspirin use in AD diagnosis.